Biotech News

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)

Amarin Corporation (AMRN)Amarin CorporationClinical readout

Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA

Related news

Amarin Corporation

Cardiovascular Therapeutics Company Amarin is a cardiovascular-focused pharmaceutical company built around prescription icosapent ethyl. Its commercial strategy combines a continuing U.S. presence with regional partners responsible for regulatory, market-access, and sales activities internationally. VASCEPA and VAZKEPA The product is...

Recent company news

Stock data

Close
11.26 USD
Market cap
303.42M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States